



An open letter to the PBC Community,

As we come together to recognize the 11th annual International Primary Biliary Cholangitis (PBC) Day on September 10, the team across Intercept is again reminded of why we do what we do and feel an immense sense of responsibility to help raise awareness of this rare and serious liver disease.

For people living with PBC and their caregivers, PBC is a journey filled with unique challenges, unparalleled strength, and the need for unwavering support. At Intercept, we recognize the courage and resilience it takes to face these challenges, and we are honored to stand as a partner in their fight.

PBC remains an area where continued research, deepened understanding, and patient support are crucial to conquering this devastating disease. While the progress made over the last decades is commendable, the journey is far from over. At Intercept, our mission includes truly understanding the lived experiences of those with PBC, to ensure that our work aligns with their needs and aspirations.

On this International PBC Day, I want to extend my gratitude to the patient advocacy groups, healthcare professionals, caregivers, families, and, most importantly, people living with PBC across the community. Your unwavering spirit, invaluable insights, and shared experiences empower us to explore new horizons in PBC research and inspire our continued support in the fight against this disease. Intercept's commitment to the PBC community remains steadfast.

Like you, we continue to strive for a future where PBC is understood and treated effectively, and where every patient feels supported and heard.

With respect,

A handwritten signature in black ink, appearing to read "Jerry Durso".

Jerry Durso
Chief Executive Officer, Intercept Pharmaceuticals